Cargando…
Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiol...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299773/ https://www.ncbi.nlm.nih.gov/pubmed/34753219 http://dx.doi.org/10.1111/ene.15174 |
_version_ | 1784751053286146048 |
---|---|
author | Garibaldi, Matteo Nicoletti, Tommaso Bucci, Elisabetta Fionda, Laura Leonardi, Luca Morino, Stefania Tufano, Laura Alfieri, Girolamo Lauletta, Antonio Merlonghi, Gioia Perna, Alessia Rossi, Salvatore Ricci, Enzo Alonso Perez, Jorge Tartaglione, Tommaso Petrucci, Antonio Pennisi, Elena Maria Salvetti, Marco Cutter, Gary Díaz‐Manera, Jordi Silvestri, Gabriella Antonini, Giovanni |
author_facet | Garibaldi, Matteo Nicoletti, Tommaso Bucci, Elisabetta Fionda, Laura Leonardi, Luca Morino, Stefania Tufano, Laura Alfieri, Girolamo Lauletta, Antonio Merlonghi, Gioia Perna, Alessia Rossi, Salvatore Ricci, Enzo Alonso Perez, Jorge Tartaglione, Tommaso Petrucci, Antonio Pennisi, Elena Maria Salvetti, Marco Cutter, Gary Díaz‐Manera, Jordi Silvestri, Gabriella Antonini, Giovanni |
author_sort | Garibaldi, Matteo |
collection | PubMed |
description | BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. METHODS: One hundred and thirty‐four DM1 patients underwent a cross‐sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. RESULTS: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR‐positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. CONCLUSIONS: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials. |
format | Online Article Text |
id | pubmed-9299773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92997732022-07-21 Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials Garibaldi, Matteo Nicoletti, Tommaso Bucci, Elisabetta Fionda, Laura Leonardi, Luca Morino, Stefania Tufano, Laura Alfieri, Girolamo Lauletta, Antonio Merlonghi, Gioia Perna, Alessia Rossi, Salvatore Ricci, Enzo Alonso Perez, Jorge Tartaglione, Tommaso Petrucci, Antonio Pennisi, Elena Maria Salvetti, Marco Cutter, Gary Díaz‐Manera, Jordi Silvestri, Gabriella Antonini, Giovanni Eur J Neurol Muscle and MNJ Disorders BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. METHODS: One hundred and thirty‐four DM1 patients underwent a cross‐sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. RESULTS: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR‐positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. CONCLUSIONS: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials. John Wiley and Sons Inc. 2021-12-06 2022-03 /pmc/articles/PMC9299773/ /pubmed/34753219 http://dx.doi.org/10.1111/ene.15174 Text en © 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Muscle and MNJ Disorders Garibaldi, Matteo Nicoletti, Tommaso Bucci, Elisabetta Fionda, Laura Leonardi, Luca Morino, Stefania Tufano, Laura Alfieri, Girolamo Lauletta, Antonio Merlonghi, Gioia Perna, Alessia Rossi, Salvatore Ricci, Enzo Alonso Perez, Jorge Tartaglione, Tommaso Petrucci, Antonio Pennisi, Elena Maria Salvetti, Marco Cutter, Gary Díaz‐Manera, Jordi Silvestri, Gabriella Antonini, Giovanni Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title | Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title_full | Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title_fullStr | Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title_full_unstemmed | Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title_short | Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials |
title_sort | muscle magnetic resonance imaging in myotonic dystrophy type 1 (dm1): refining muscle involvement and implications for clinical trials |
topic | Muscle and MNJ Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299773/ https://www.ncbi.nlm.nih.gov/pubmed/34753219 http://dx.doi.org/10.1111/ene.15174 |
work_keys_str_mv | AT garibaldimatteo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT nicolettitommaso musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT buccielisabetta musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT fiondalaura musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT leonardiluca musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT morinostefania musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT tufanolaura musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT alfierigirolamo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT laulettaantonio musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT merlonghigioia musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT pernaalessia musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT rossisalvatore musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT riccienzo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT alonsoperezjorge musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT tartaglionetommaso musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT petrucciantonio musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT pennisielenamaria musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT salvettimarco musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT cuttergary musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT diazmanerajordi musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT silvestrigabriella musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials AT antoninigiovanni musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials |